Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Breadcrumb

  1. Home
  2. Vantage
  3. Topics
  4. Deals
  5. Alliances Collaborations Licensing
  6. Co Promotion

Co-promotion

Evaluate

Thumbnail
April 13, 2023

Zealand seeks deals in obesity and beyond

With Boehringer locked in, the Danish biotech wants more partners for monotherapies, combos and more.

Thumbnail
March 27, 2023

With its eyes on a bigger prize, Pfizer cuts Bavencio loose

Article image
Vantage logo
October 06, 2022

Sanofi dips a toe back into diabetes

Article image
Vantage logo
May 04, 2022

The next generation of diabetes technology

New devices are coming, but the real advances will involve combinations.

Article image
Vantage logo
March 17, 2022

Merck looks for a return on its Lynparza investment

Merck & Co has sunk billions into Lynparza, but its Keytruda combo plan, which it is funding solely, just got off to a rocky start.

Article image
Vantage logo
March 15, 2022

Eisai leaves Biogen holding the Aduhelm baby

The Japanese group doubles down on lecanemab while somehow disentangling itself from the Aduhelm mess.

Article image
Vantage logo
September 27, 2021

Incyte turns to in-licensing

Article image
Vantage logo
June 01, 2021

Amgen follows Sanofi into a new dermatitis mechanism

The move shines a light on Ichnos, though none of the groups with clinical-stage Ox40 blockers has yet reported full phase 2 data.

Article image
Vantage logo
October 28, 2020

Another complement factor enters the deal-making frame

Sobi picking up rights to Apellis’s complement factor C3 inhibitor adds to earlier deals focused on C5, D and anti-FcRn antibodies.

Article image
Vantage logo
August 07, 2020

Biogen pays $560m for an unproven Parkinson’s mechanism

All the attention is on aducanumab, but yesterday’s deal with Denali is a reminder that Biogen has other irons in the fire.

Article image
Vantage logo
April 15, 2020

Another endorsement for PI3K delta, this time in oncology

  • Load More
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

May 15, 2023

Pharma’s Biggest Spenders 2022 Infographic

May 03, 2023

Gene Editing: Overhyped or Unstoppable Tide?

View more...

Editor's Picks

Vantage logo
May 16, 2023

Heightened US antitrust fears rattle biopharma

Vantage logo
May 11, 2023

2023’s biggest launches: the story so far

Vantage logo
May 17, 2023

Viking’s Voyage is not over yet

Vantage logo
May 09, 2023

Gene editing: overhyped or unstoppable tide?

Vantage logo
May 16, 2023

A slow (and low) year for FDA approvals

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-80-1164-4754

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy
  • Modern Slavery Statement

© Copyright 2023 Evaluate Ltd.

Sign up